Popular
Why Adenoma Detection Rate Matters in Colorectal Cancer Screening
Clinician's RoundtableWhy Adenoma Detection Rate Matters in Colorectal Cancer Screening
Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
CME/CENavigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
CardiologySCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
"You don't have to know programming to create solutions," says Dr. Michal Nedoszytko, Creator of PostVisit.ai
The Convergence"You don't have to know programming to create solutions," says Dr. Michal Nedoszytko, Creator of PostVisit.ai
Programs
Why Adenoma Detection Rate Matters in Colorectal Cancer Screening
Clinician's RoundtableWhy Adenoma Detection Rate Matters in Colorectal Cancer Screening
Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Project Oncology®Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
MinuteCE®When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Are E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
AudioAbstractsAre E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
FcRn: Same Class, Different Paths—Spot Agent Differentiators
MinuteCE®FcRn: Same Class, Different Paths—Spot Agent Differentiators
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
MinuteCE®From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Clinical Practice
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
CME/CEChairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Turning Flares Into Function: Flag Uncontrolled Disease
MinuteCE®Turning Flares Into Function: Flag Uncontrolled Disease
Neuroplasticity: A Potential Target for the Treatment of Depression
Medical Industry FeatureNeuroplasticity: A Potential Target for the Treatment of Depression
Gaps in Shingles Vaccination: What Clinicians Need to Know
VacciNationGaps in Shingles Vaccination: What Clinicians Need to Know
Doctors Lounge
Next-Gen Clinical Monitoring: Predicting Inpatient Decline with AI-Driven Alerts
The ConvergenceNext-Gen Clinical Monitoring: Predicting Inpatient Decline with AI-Driven Alerts
“We see 40 million Americans a day using ChatGPT for health and wellness-related questions,” says Kate Rouch from OpenAI
The Convergence“We see 40 million Americans a day using ChatGPT for health and wellness-related questions,” says Kate Rouch from OpenAI
Disparities in Osteoporosis Care: Addressing Screening and Treatment Barriers
On the Frontlines of OsteoporosisDisparities in Osteoporosis Care: Addressing Screening and Treatment Barriers
Disparities in Acne Prescribing Patterns Highlight Structural and Racial Gaps
Clinician's RoundtableDisparities in Acne Prescribing Patterns Highlight Structural and Racial Gaps
Uncovering Disparities in Teleneurology Utilization Post-Pandemic
On the Frontlines of Multiple SclerosisUncovering Disparities in Teleneurology Utilization Post-Pandemic
"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
The Convergence"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
CME
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
MinuteCE®Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Applying Advances in Practice: Case-Based Look at Selecting Therapy for Cushing Syndrome
CME/CEApplying Advances in Practice: Case-Based Look at Selecting Therapy for Cushing Syndrome
Molecular Precision: How Myosin Inhibitors Redefine Control
MinuteCE®Molecular Precision: How Myosin Inhibitors Redefine Control
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CEStuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CETransforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Industry Feature
Living with Psoriatic Arthritis: A Doctor-Patient Conversation
Medical Industry FeatureLiving with Psoriatic Arthritis: A Doctor-Patient Conversation
Anti-Amyloid Therapy in Early Alzheimer’s Disease: Real-World Experience and Innovation
Medical Industry FeatureAnti-Amyloid Therapy in Early Alzheimer’s Disease: Real-World Experience and Innovation
Breakthrough Technology Improves Concussion Assessment and Player Safety
Medical Industry FeatureBreakthrough Technology Improves Concussion Assessment and Player Safety
Improving Outcomes and Reducing Delays in Orthopedic Surgery
Medical Industry FeatureImproving Outcomes and Reducing Delays in Orthopedic Surgery
Rethinking Cardiovascular Risk: Uncovering the Blind Spots
Conversations in CV Risk AssessmentRethinking Cardiovascular Risk: Uncovering the Blind Spots
Challenging Cases in IgA Nephropathy and Identifying Patients for Specialized Care
Medical Industry FeatureChallenging Cases in IgA Nephropathy and Identifying Patients for Specialized Care